The Lancet January 22, 2000

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy

Heart Outcomes Prevention Evaluation (HOPE) Study Investigators

Bottom Line

The MICRO-HOPE substudy demonstrated that the ACE inhibitor ramipril significantly reduces the risk of major cardiovascular events, total mortality, and overt nephropathy in high-risk patients with diabetes, independent of its blood pressure-lowering effects.

Key Findings

1. The primary composite outcome (myocardial infarction, stroke, or cardiovascular death) occurred in 15.3% of the ramipril group versus 19.8% of the placebo group, yielding a 25% relative risk reduction (95% CI 12-36; p=0.0004).

2. Ramipril significantly reduced the individual incidences of cardiovascular death (6.2% vs. 9.7%; RRR 37%), myocardial infarction (10.2% vs. 12.9%; RRR 22%), and stroke (4.2% vs. 6.1%; RRR 33%).

3. Total mortality was substantially lower in the ramipril arm compared to placebo (10.8% vs. 14.0%; RRR 24%, p=0.004).

4. Ramipril conferred significant microvascular protection, reducing the risk of developing new overt nephropathy by 24% (6.5% vs. 8.4%; p=0.027).

5. The 25% reduction in the primary composite outcome remained statistically significant (p=0.0004) even after adjusting for the modest differences in office systolic (2.4 mmHg) and diastolic (1.0 mmHg) blood pressures between the treatment arms.

Study Design

Design

Double-Blind, Randomized Controlled Trial

Double-Blind

Sample

3,577

Patients

Duration

4.5 yr

Median

Setting

Multicenter, 19 countries

Population Patients aged ≥55 years with diabetes and a previous cardiovascular event or ≥1 other cardiovascular risk factor, without clinical proteinuria, heart failure, or low ejection fraction.

Intervention Ramipril 10 mg daily

Comparator Matching placebo

Outcome Composite of myocardial infarction, stroke, or cardiovascular death

Study Limitations

• The trial was terminated 6 months early (at 4.5 years) by the independent data safety and monitoring board due to overwhelming benefit, which can sometimes result in a slight overestimation of the treatment effect size.

• While statistically adjusted for, debate persisted regarding whether single office blood pressure measurements adequately captured the true hemodynamic differences, as 24-hour ambulatory blood pressure differences may have been larger and contributed more heavily to the outcomes.

• The study enrolled a predominantly older (≥55 years), high-risk diabetic population, which may limit the generalizability of the absolute risk reductions to younger, lower-risk diabetic patients.

Clinical Significance

MICRO-HOPE fundamentally shifted the paradigm of diabetes management and cardiovascular prevention. Prior to this trial, ACE inhibitors were mainly indicated for treating hypertension, established heart failure, or diabetic nephropathy. MICRO-HOPE proved that ACE inhibition with ramipril provides broad vasculoprotective and renoprotective benefits in high-risk diabetic patients irrespective of baseline blood pressure, leading to international guideline changes that aggressively recommended ACE inhibitors for cardiovascular risk reduction in this population.

Historical Context

During the 1990s, secondary cardiovascular prevention heavily focused on lipid lowering and antiplatelet therapy. While ACE inhibitors had proven efficacy in patients with heart failure and post-MI left ventricular dysfunction (demonstrated in trials like SOLVD and SAVE), their role in patients with preserved ventricular function was unknown. The overarching HOPE trial, and the pre-specified MICRO-HOPE diabetic cohort in particular, served as a landmark moment that supported the 'tissue ACE' theory—suggesting that ACE inhibitors independently stabilize plaques, improve endothelial function, and reduce oxidative stress—cementing their status as cornerstone therapies for diabetic prophylaxis.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the pathophysiological mechanism by which ACE inhibitors like ramipril confer cardiovascular and renal protection in diabetic patients, beyond their systemic blood pressure-lowering effects?

Key Response

ACE inhibitors reduce angiotensin II-mediated efferent arteriolar vasoconstriction, thereby decreasing intraglomerular pressure and microalbuminuria. Additionally, they decrease local tissue angiotensin II and increase bradykinin, which reduces oxidative stress, endothelial dysfunction, and vascular remodeling, explaining the tissue-level benefits observed in MICRO-HOPE.

Resident

Based on the MICRO-HOPE findings, which diabetic patients should be empirically started on an ACE inhibitor even if they are normotensive, and what clinical parameters must you monitor shortly after initiation?

Key Response

MICRO-HOPE supports starting ACE inhibitors in diabetic patients aged 55 or older with at least one other cardiovascular risk factor regardless of baseline blood pressure. Residents must monitor serum creatinine and potassium 1 to 2 weeks post-initiation to check for hyperkalemia or acute kidney injury, which may indicate underlying bilateral renal artery stenosis.

Fellow

The MICRO-HOPE study suggests ramipril's benefits are largely independent of blood pressure reduction given the small clinic BP differences. How does the concept of nocturnal blood pressure dipping and ambulatory monitoring complicate the assertion that these benefits are purely pleiotropic?

Key Response

While clinic BP differences in HOPE were minimal (2-3 mmHg), 24-hour ambulatory monitoring in similar cohorts shows ACE inhibitors effectively restore nocturnal BP dipping and provide continuous hemodynamic offloading. Furthermore, high-tissue-affinity ACE inhibitors alter local microvascular hemodynamics not captured by brachial cuff measurements, blurring the line between pleiotropic and hemodynamic benefits.

Attending

When teaching junior clinicians about cardiovascular risk reduction in diabetes, how do you use the MICRO-HOPE data to reframe the therapeutic goal of RAAS inhibition from treating a specific vital sign to treating a systemic disease state?

Key Response

Attendings should emphasize that waiting for overt hypertension to develop before initiating an ACE inhibitor in high-risk diabetics misses a critical window for organ protection. MICRO-HOPE shifted the paradigm from targeting a blood pressure threshold to utilizing disease-modifying therapy, teaching trainees to prescribe based on comprehensive cardiovascular risk and endothelial dysfunction.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The MICRO-HOPE study is a predefined substudy of the larger HOPE trial. What are the statistical risks of evaluating secondary endpoints in a substudy, and how does the presence of interaction terms affect the interpretation of the treatment effect across diabetic versus non-diabetic strata?

Key Response

Subgroup analyses often suffer from multiplicity and inadequate power. While MICRO-HOPE was predefined with a large sample size, researchers must scrutinize the formal interaction tests (p-values for interaction) to confirm whether the treatment effect size is distinctly modified by the diabetic state or simply reflects the overall trial's homogenous effect applied to a higher baseline risk group.

Journal Editor

As a peer reviewer assessing the MICRO-HOPE manuscript, what concerns might you raise regarding the early termination of the trial by the data monitoring committee, and how could this affect the estimated magnitude of ramipril's treatment effect?

Key Response

The HOPE trial was stopped early due to clear, statistically significant benefits. A rigorous reviewer would flag that early truncation of clinical trials often exaggerates the treatment effect size (a random high), potentially leading to an overestimation of the absolute risk reduction for cardiovascular events and overt nephropathy in the diabetic cohort.

Guideline Committee

How does the MICRO-HOPE substudy inform current ADA and ACC/AHA guideline recommendations regarding the use of ACE inhibitors in normotensive diabetic patients, and what level of evidence does it provide for primary versus secondary cardiovascular prevention?

Key Response

MICRO-HOPE provided foundational Level A evidence for ADA and ACC/AHA guidelines to strongly recommend ACE inhibitors for diabetic patients with additional cardiovascular risk factors, even without hypertension. The committee evaluates this as robust evidence for high-risk primary and secondary prevention, cementing RAAS blockade as a cornerstone in modern diabetes management guidelines.

Clinical Landscape

Noteworthy Related Trials

2001

RENAAL Trial

n = 1,513 · NEJM

Tested

Losartan 50-100mg daily

Population

T2DM patients with nephropathy

Comparator

Placebo

Endpoint

Composite of doubling of serum creatinine, ESRD, or death

Key result: Losartan significantly reduced the incidence of a doubling of the serum creatinine concentration, end-stage renal disease, or death by 16 percent.

2008

ADVANCE Trial

n = 11,140 · Lancet

Tested

Perindopril/indapamide fixed-dose combination

Population

T2DM patients with high cardiovascular risk

Comparator

Placebo

Endpoint

Composite of major macrovascular and microvascular events

Key result: Routine administration of perindopril/indapamide reduced the relative risk of major vascular events by 9 percent, driven mainly by a reduction in renal events.

2008

ONTARGET Trial

n = 25,620 · NEJM

Tested

Telmisartan 80mg daily

Population

Patients with vascular disease or high-risk diabetes without heart failure

Comparator

Ramipril 10mg daily and combination therapy

Endpoint

Composite of CV death, MI, stroke, or hospitalization for heart failure

Key result: Telmisartan was equivalent to ramipril for preventing vascular events in high-risk patients, while the combination therapy actually worsened renal outcomes.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis